Fujifilm Medical Systems U.S.A. Inc. recently introduced the FCT Embrace computed tomography (CT) system. Powered by Analogic, the FCT Embrace is the world’s first 85cm wide bore CT imaging unit with 64- or 128-slice configurations, according to the company. Optimized for both oncology and radiology applications, the FCT Embrace, combined with other oncology solutions, offers enhanced and efficient CT simulation with radiotherapy treatment planning capabilities. The unveiling during the 2018 American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Texas, marks Fujifilm’s entry into the CT market.

Varian announced its new single-room proton therapy system, ProBeam 360°, at the 2018 American Society of Radiation Oncology (ASTRO) annual meeting, Oct. 21-24 in San Antonio, Texas. With a 30 percent smaller footprint than the previous system, ProBeam 360° offers uncompromised clinical capabilities, according to Varian, while reducing vault construction costs by approximately 25 percent. The new system has a 360-degree rotating gantry, a powerful particle accelerator, iterative cone-beam computed tomography (CBCT) imaging and high-definition pencil-beam scanning technology. The system can also provide clinicians a viable path to potential next-generation treatments such as Flash therapy.

Magnetic resonance imaging (MRI) measurements of wall thickness in the carotid arteries improve cardiovascular disease risk assessment, according to a new study appearing in the journal Radiology.

Amar U. Kishan, M.D., presents data about stereotactic body radiation therapy at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
ITN Contributing Editor Greg Freiherr interviews researchers about SBRT results.

With its shorter course of treatment, stereotactic body radiation therapy (SBRT) has long been preferred for patients with prostate cancer, particularly given that this form of cancer has appeared to be more sensitive to higher doses per treatments. Concern has lingered, however, about its safety. Those concerns have been put to rest for low and intermediate-risk prostate cancer, according to a researcher from the University of California, Los Angeles.

Whole-brain radiotherapy can be delivered more safely to patients with brain metastases by avoiding the hippocampus, according to a randomized phase III NRG Oncology trial. Trial results were presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 21-24 in San Antonio, Texas.

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.

The first report of a large, international clinical trial shows that, for men who show signs of prostate cancer after surgical removal of their prostates, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads.

Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one kidney as it is for those who have two, according to an analysis of the largest-ever, international dataset of solitary kidney patients to receive this emerging treatment. The findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now